Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)

Trial Profile

Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs Ambrisentan (Primary)
  • Indications Pulmonary hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 03 Jan 2018 New trial record
    • 27 Dec 2017 Results (n=702) of interim analysis assessing safety and efficacy, published in the Clinical Drug Investigation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top